Levodopa in Parkinson's disease: from the past to the future

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2010-02-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656561003598919PMID 20163273
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Pharmacokinetics of levodopa

  2010cited by this paper
• [Non-motor fluctuations in Parkinson's disease].

  2010cited by this paper
• A Double-Blind, Delayed-Start Trial of Rasagiline In Parkinson's Disease

  2010cited by this paper
• Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

  2009cited by this paper
• Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.

  2009cited by this paper
• A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

  2009cited by this paper
• Can we achieve neuroprotection with currently available anti-parkinsonian interventions?

  2009cited by this paper
• Cells therapy for Parkinson’s disease—so close and so far away

  2009cited by this paper
• New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer.

  2008cited by this paper
• Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease

  2008cited by this paper
• Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

  2007cited by this paper
• Clinical Efficacy of a Single Afternoon Dose of Effervescent Levodopa-Carbidopa Preparation (CHF 1512) in Fluctuating Parkinson Disease

  2007cited by this paper
• Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome

  2007cited by this paper
• Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease.

  2006cited by this paper
• Survival of Parkinson's disease patients in a large prospective cohort of male health professionals

  2006cited by this paper
• Epidemiology of Parkinson's disease.

  2006cited by this paper
• Optimising levodopa therapy for the management of Parkinson’s disease

  2005cited by this paper
• Optimising levodopa therapy for the management of Parkinson’s disease

  2005cited by this paper
• Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

  2005cited by this paper
• Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model.

  2005cited by this paper
• Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

  2005cited by this paper
• Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.

  2005cited by this paper
• A Pulmonary Formulation of l-Dopa Enhances Its Effectiveness in a Rat Model of Parkinson's Disease

  2004cited by this paper
• Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa.

  2004cited by this paper
• Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies

  2004cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms

  2004cited by this paper
• Neural transplantation for the treatment of Parkinson's disease.

  2003cited by this paper
• Neuropsychiatric non-motor aspects of Parkinson’s disease

  2003cited by this paper
• Evolution and cell biology of dopamine receptors in vertebrates

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003influential reference
• Levodopa strengths and weaknesses

  2002cited by this paper
• The neurobiology of dopamine signaling

  2002cited by this paper
• Neural transplantation for treatment of Parkinson's disease.

  2002cited by this paper
• Parkinson’s disease and sleepiness: An integral part of PD

  2002cited by this paper
• Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling

  2002cited by this paper
• Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review

  2002cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• Cell therapy for Parkinson's disease.

  2001cited by this paper
• Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

  2001cited by this paper
• Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

  2001cited by this paper
• Enhancement of the Systemic and CNS Specific Delivery of L-Dopa by the Nasal Administration of Its Water Soluble Prodrugs

  2000cited by this paper
• Levodopa motor complications in Parkinson's disease.

  2000cited by this paper
• Continuous dopamine-receptor stimulation in advanced Parkinson's disease.

  2000cited by this paper
• Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.

  2000cited by this paper
• Transdermal Absorption of L-Dopa from a New System Composed of two Separate Layers of L-Dopa and Hydrogel in Rats

  2000cited by this paper
• Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

  2000cited by this paper
• Transport of drugs from the nasal cavity to the central nervous system.

  2000cited by this paper
• Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint

  1999cited by this paper
• Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.

  1999cited by this paper
• Parkinson's disease. First of two parts.

  1998cited by this paper
• Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease

  1998cited by this paper
• Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients

  1997cited by this paper
• Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET

  1996cited by this paper
• Neuropathology of Parkinson's Disease

  1996cited by this paper
• The response to levodopa in parkinson's disease: Imposing pharmacological law and order

  1996cited by this paper
• Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease.

  1995cited by this paper
• Wearing‐off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms

  1994cited by this paper
• Motor response to repeated dopaminergic stimulation in Parkinson's disease.

  1992cited by this paper
• The dopamine receptor family: molecular biology and pharmacology

  1992cited by this paper
• The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras.

  1992cited by this paper
• Stereotaxic implantation of autologous adrenal medulla into caudate nucleus in four patients with parkinsonism. One-year follow-up.

  1991cited by this paper
• Monoamine oxidase, dopamine and Parkinson's disease

  1991cited by this paper
• An estimate of the incidence of dementia in idiopathic Parkinson's disease

  1990cited by this paper
• Jejunal delivery of levodopa methyl ester.

  1989cited by this paper
• Parkinson's Disease and Movement Disorders

  1988cited by this paper
• Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonism

  1988cited by this paper
• Depression and disability in Parkinson's disease: a follow-up of 132 cases

  1988cited by this paper
• The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.

  1986cited by this paper
• Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations

  1986cited by this paper
• The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism

  1985cited by this paper
• Pharmacokinetics of levodopa.

  1984cited by this paper
• The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

  1984cited by this paper
• The site of dopamine formation in rat striatum after L-dopa administration.

  1981cited by this paper
• 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.

  1975cited by this paper
• 3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier

  1975cited by this paper
• One-year follow-up

  1975cited by this paper
• Active Transport of L-Dopa in the Intestine

  1973cited by this paper
• Levodopa in the treatment of Parkinsonism.

  1971influential reference
• L-dopa in Parkinson's disease.

  1970cited by this paper
• Aromatic amino acids and modification of parkinsonism.

  1967cited by this paper
• Konjugation micronucleusloser Paramaecien

  1939cited by this paper

• Management of osteoporosis in Parkinson's disease: A scoping review.

  2025cites this paper
• Bioequivalence of Foslevodopa/Foscarbidopa continuous subcutaneous infusion to arm, thigh, or flank versus abdomen in healthy and advanced Parkinson’s disease individuals

  2025influential citation
• Does drug repurposing bridge the gaps in management of Parkinson's disease? Unravelling the facts and fallacies.

  2025cites this paper
• Feasibility, safety and efficacy of multi-dose vagus nerve stimulation in Parkinson’s disease: a double-blind, randomised sham-controlled proof-of-concept study

  2025cites this paper
• Deciphering the molecular and neuropathological dimensions of dementia

  2025cites this paper
• Nicotinamide Riboside Ameliorates Survival Time and Motor Dysfunction in an MPTP-Induced Parkinson's Disease Zebrafish Model through Effects on Glucose Metabolism and Endoplasmic Reticulum Stress.

  2024cites this paper
• Rhamnosomes: A new generation of flexible vesicles for a boosted targeted nose-to-brain delivery of selegiline in the treatment of Parkinson's disease

  2024cites this paper
• Comparative Molecular Docking Studies of Selected Phytoconstituents on the Dopamine D3 Receptor (PDB ID: 3PBL) as Potential Anti-Parkinson’s Agents

  2023cites this paper
• Clinical Evaluation in Parkinson’s Disease: Is the Golden Standard Shiny Enough?

  2023cites this paper
• Endophytic Fusarium species, a unique bioresource for disaggregator of misfolded alpha-synuclein

  2023cites this paper
• Treatment of Parkinson's Disease: Current Treatments and Recent Therapeutic Developments.

  2023cites this paper
• Engineering Regionally-Activated Drugs for Neuroscience

  2023cites this paper
• Intergenerational choral singing to improve communication outcomes in Parkinson’s disease: Development of a theoretical framework and an integrated measurement tool

  2022cites this paper
• Striatal D1 Dopamine Neuronal Population Dynamics in a Rat Model of Levodopa-Induced Dyskinesia

  2022cites this paper
• Tilianin attenuates MPP+-induced oxidative stress and apoptosis of dopaminergic neurons in a cellular model of Parkinson's disease

  2022cites this paper
• Chronobiology of Parkinson's disease: Past, present and future

  2022cites this paper
• Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis

  2022cites this paper
• Levodopa-Loaded 3D-Printed Poly (Lactic) Acid/Chitosan Neural Tissue Scaffold as a Promising Drug Delivery System for the Treatment of Parkinson’s Disease

  2021cites this paper
• Predication of the Underlying Protective Effect of Saffron on Parkinson's Disease via Network Pharmacology and Molecular Docking

  2021cites this paper
• Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson’s Disease: An Updated Review

  2021cites this paper
• Curcumin loaded drug delivery systems in Parkinson’s disease

  2021cites this paper
• A systematic review of active group-based dance, singing, music therapy and theatrical interventions for quality of life, functional communication, speech, motor function and cognitive status in people with Parkinson’s disease

  2020cites this paper
• Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease.

  2020cites this paper
• Liver Growth Factor Induces Glia-Associated Neuroprotection in an In Vitro Model of Parkinson´s Disease

  2020cites this paper
• PHARMACOLOGICAL STUDIES ON PLANTS BELONGING TO THE FAMILY LEGUMINOSAE

  2020cites this paper
• Understanding the pathogenesis involved in Parkinson's disease and potential therapeutic treatment strategies.

  2020cites this paper
• Boc-phenylalanine Grafted Poly(3,4-propylenedioxythiophene) Film for Electrochemically Chiral Recognition of 3,4-Dihydroxyphenylalanine Enantiomers

  2019cites this paper
• Pilose Antler Extracts (PAEs) Protect against Neurodegeneration in 6-OHDA-Induced Parkinson's Disease Rat Models

  2019cites this paper
• Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy

  2018cites this paper
• Innovation in Formulation Development for Older People

  2018cites this paper
• Chiral recognition of dihydroxyphenylalanine enantiomers with (R)/(S)-2-Phenylpropionic acid grafted PProDOT electrochemical sensors

  2018cites this paper
• Managing Gait, Balance, and Posture in Parkinson’s Disease

  2018cites this paper
• Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade.

  2018cites this paper
• Protection of nigral dopaminergic neurons by AAV1 transduction with Rheb(S16H) against neurotoxic inflammation in vivo

  2018cites this paper
• Dopa-sensibilité et Dopa-résistance : autant de réponses que de symptômes

  2017cites this paper
• Passiflora cincinnata Extract Delays the Development of Motor Signs and Prevents Dopaminergic Loss in a Mice Model of Parkinson's Disease

  2017cites this paper
• Protective effects of DL‑3‑n‑butylphthalide in the lipopolysaccharide‑induced mouse model of Parkinson's disease.

  2017cites this paper
• Synthesis and characterization of D-/L-methionine grafted PEDOTs for selective recognition of 3,4-dihydroxyphenylalanine enantiomers

  2016cites this paper
• Poly(3,4-Ethylenedioxythiophene) Derivatives with Electrochemical Chiral Sensor for 3,4-Dihydroxyphenylalanine Discrimination

  2016cites this paper
• Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP.

  2016cites this paper
• Potential Benefit of Singing for People with Parkinson’s Disease: A Systematic Review

  2016cites this paper
• Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism.

  2016cites this paper
• Altérations du système de récompense dans la maladie de Parkinson : relation entre comportement et signatures moléculaires. : Neuropsychopharmacologie.

  2016cites this paper
• Synthesis of Novel Chiral L-Phenylalanine Grafted PEDOT Derivatives with Electrochemical Chiral Sensor for 3,4-Dihydroxyphenylalanine Discrimination

  2015cites this paper
• Therapy-resistant symptoms in Parkinson’s disease

  2015cites this paper
• Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.

  2015cites this paper
• Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease

  2014cites this paper
• Chiral capillary electromigration techniques—mass spectrometry—hope and promise

  2014cites this paper
• Hematopoietic stem cells improve dopaminergic neuron in the MPTP-mice.

  2013cites this paper
• The potential mechanisms for motor complications of Parkinson's disease

  2013cites this paper
• Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.

  2012cites this paper
• Role of alpha6 nicotinic receptors in CNS dopaminergic function; relevance to addiction and neurological disorders

  2012cites this paper
• Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson's disease

  2011cites this paper
• Chiral Capillary Electrophoresis-Mass Spectrometry of DOPA: Evidence for Its Enantioselective Metabolism in PC-12 Nerve Cells

  2011cites this paper
• Parkinson's Disease Dementia and Potential Therapeutic Strategies

  2011cites this paper
• Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

  2011cites this paper
• Pharmacological challenge and synaptic response – assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET)

  2011cites this paper
• Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.

  2011cites this paper
• Camptocormia in Parkinson’s Disease: A Review of the Literature

  2011cites this paper
• Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson ’ s Disease

  2011cites this paper
• α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease

  2011cites this paper
• Inhibition of experimental myopia by a dopamine agonist: different effectiveness between form deprivation and hyperopic defocus in guinea pigs

  2011cites this paper
• Chiral capillary electrophoresis-mass spectrometry of 3,4-dihydroxyphenylalanine: evidence for its enantioselective metabolism in PC-12 nerve cells.

  2011cites this paper
• Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.

  2011cites this paper
• Investigating the Role of Synapsin II in Neurological Disorders Involving Dysregulated Dopaminergic Transmission

  2010cites this paper
• Modern-day naturopathic medicine and traditional Ayurveda in a combined attack against Parkinson's disease

  2010influential citation
• Universidade Federal do Rio Grande do Sul Instituto de Ciências Básica da Saúde Programa de Pós-Graduação em Neurociências

  2010cites this paper